Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel
- PMID: 32452013
- DOI: 10.1007/s13577-020-00373-3
Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel
Abstract
The chemoresistance of tumors is the main barrier to cancer treatment. Interleukin-22 (IL-22) plays an important role in the chemoresistance of multi-cancers; however, the roles of IL-22 in the paclitaxel resistance of lung adenocarcinoma cells remain to be investigated. The present study aims to investigate the potential mechanisms of IL-22 enhancing the chemoresistance of lung adenocarcinoma cells to paclitaxel. We cultured A549, H358, and A549/PTX cell lines. qRT-PCR and western blot assays were performed to examine the mRNA and/or protein levels of IL-22 in A549, A549/PTX, H358, and H358/PTX. Moreover, cells were transfected with IL-22 siRNA1, IL-22 siRNA2, and siRNA NC, and treated with paclitaxel, and the proliferation rate of lung adenocarcinoma cells was evaluated by MTT assay. Flow cytometry was conducted to determine the apoptosis rate of lung adenocarcinoma cells. The results showed that the expression of IL-22 in lung adenocarcinoma tissues was higher than that in normal tissues, and the expression of IL-22 was higher in A549/PTX and H358/PTX compared with A549 and H358 cells. Meanwhile, the expression of IL-22 was strongly correlated with smoking history and TMN stage, as well. Furthermore, IL-22 siRNA inhibited the proliferation and promoted the apoptosis of A549/PTX and H358/PTX cells, and IL-22 siRNA also suppressed the expression levels of AKT and Bcl-2 and increased the expression levels of Bax and cleaved caspase 3. To sum up, IL-22 may mediate the chemosensitivity of lung adenocarcinoma cells to paclitaxel through inhibiting the AKT signaling pathways.
Keywords: Apoptosis; Chemoresistance; IL-22; Lung adenocarcinoma; Proliferation.
Similar articles
-
Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway.Med Sci Monit. 2018 May 3;24:2750-2757. doi: 10.12659/MSM.907336. Med Sci Monit. 2018. PMID: 29723165 Free PMC article.
-
Upregulation of Neural Precursor Cell Expressed Developmentally Downregulated 4-1 is Associated with Poor Prognosis and Chemoresistance in Lung Adenocarcinoma.Chin Med J (Engl). 2018 Jan 5;131(1):16-24. doi: 10.4103/0366-6999.221262. Chin Med J (Engl). 2018. PMID: 29271375 Free PMC article.
-
XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.Oncol Rep. 2019 Mar;41(3):1875-1882. doi: 10.3892/or.2019.6959. Epub 2019 Jan 9. Oncol Rep. 2019. PMID: 30628719
-
[nm23-H1-siRNA enhances the chemosensitivity to liposome-encapsulated paclitaxel in lung adenocarcinoma cells in vitro].Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):405-9. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21875478 Chinese.
-
KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells.Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):639-647. doi: 10.1080/21691401.2020.1728287. Artif Cells Nanomed Biotechnol. 2020. PMID: 32064933
Cited by
-
Effect of 23‑hydroxybetulinic acid on lung adenocarcinoma and its mechanism of action.Exp Ther Med. 2024 Mar 28;27(6):239. doi: 10.3892/etm.2024.12527. eCollection 2024 Jun. Exp Ther Med. 2024. PMID: 38633355 Free PMC article.
-
The role of IL-22 in cancer.Med Oncol. 2024 Sep 5;41(10):240. doi: 10.1007/s12032-024-02481-8. Med Oncol. 2024. PMID: 39231878 Review.
-
miR-378d suppresses malignant phenotype of ESCC cells through AKT signaling.Cancer Cell Int. 2021 Dec 22;21(1):702. doi: 10.1186/s12935-021-02403-y. Cancer Cell Int. 2021. PMID: 34937563 Free PMC article.
-
IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer.Heliyon. 2024 Aug 10;10(17):e35901. doi: 10.1016/j.heliyon.2024.e35901. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39263114 Free PMC article. Review.
References
-
- Kobayashi K, Naoki K, Manabe T, Masuzawa K, Hasegawa H, Yasuda H, Kawada I, Soejima K, Betsuyaku T. Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. Onco Targets Ther. 2018;11:3335–43. - PubMed - PMC - DOI
-
- Liu B, Qin J, Zhou J. Advances in the Treatment of relapsed small cell lung cancer. Chin J Lung Cancer. 2017;20(3):192–8. - DOI
-
- Lin D, Han X-G, Bing T, Wang M-Q, Qiao H, Zhang S-H, Fan Q-M. CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis. Cell Death Dis. 2018;9(7):714. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials